Dr. Postow Discusses Combination Therapy for Melanoma

Michael A. Postow, MD
Published: Tuesday, Dec 05, 2017



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

There are many new combination therapies for patients with melanoma, says Postow. In the BRAF-mutant population, there are combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into phase III trials.

Immunotherapy combinations are also moving forward in clinical trials as well, adds Postow. Namely, combinations of IDO blockers and PD-1 agents.
 


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

There are many new combination therapies for patients with melanoma, says Postow. In the BRAF-mutant population, there are combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into phase III trials.

Immunotherapy combinations are also moving forward in clinical trials as well, adds Postow. Namely, combinations of IDO blockers and PD-1 agents.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x